Still to be approved inclisiran gets red carpet treatment by UK's NHS in deal with Novartis
It may not have yet secured approval, nor reviewed by UK’s price-effectiveness watchdog NICE — but the cholesterol therapy inclisiran at the heart of last year’s Novartis $9.7 billion buyout of the Medicines Company will be made widely available to patients at risk of heart disease in the National Health Service (NHS), the UK agency said on Monday.
NHS England will agree to a population-level commercial arrangement with Novartis to make it widely available to patients as soon as 2021 — in addition, the biannual shot will also be tested in UK patients as part of a large-scale NHS clinical trial expected to start later this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.